Journal Article

FZJ-2015-03679

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Ritter, C.FZJ* ; Förster, D. ; Albrecht, P. ; Hartung, H.-P. ; Kieseier, B. C. ; Lehmann, H. C. (Corresponding Author)

2014
Elsevier Science Amsterdam [u.a.]

This record in other databases:      

Please use a persistent id in citations: doi:10.1016/j.jneuroim.2014.06.007

Abstract: Recent studies indicate that the cytokine B-cell activating factor (BAFF) is involved in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is standard treatment for CIDP and is known to rapidly modulate increased serum levels of pro-inflammatory cytokines. We evaluated the expression profile of BAFF and its corresponding BAFF-receptor in samples from CIDP patients, focusing on rapid changes before and after IVIg treatment. In CIDP patients BAFF serum concentrations were elevated compared to controls. Treatment with high-dose IVIg restored those elevated BAFF serum levels. Whereas treatment with IVIg did not affect BAFF production in monocytes, antibodies against BAFF could be detected in IVIg preparations, which may explain the short-term decrease of BAFF levels after IVIg treatment. Our data suggest that BAFF plays an important role in the pathogenesis of CIDP and may serve as marker for IVIg treatment response.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333) (POF2-333)

Appears in the scientific report 2015

---

Database coverage:
; BIOSIS Previews ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---